ClinicalTrials.gg
RecruitingNCT07150013Updated Sep 17, 2026

Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome

A Phase 1 interventional study of Vorinostat (SAHA) and Placebo in Rett Syndrome, sponsored by Unravel Biosciences, Inc.. Recruiting at 1 site in Colombia. Open to female participants aged 6 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Unravel Biosciences, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
6 Years to 21 Years
Sex
Female
01

Study summary

The RETT REVOLUTION trial is a placebo-controlled, single-blinded, exploratory study with patients serving as their own control ("N of 1" trial design) where the safety and efficacy of vorinostat in the treatment of Rett syndrome will be evaluated. Each patient will be self-controlled in an adapted N-of-1 study design methodology by using a 4-week placebo baseline. Vorinostat dose escalation will occur every 8 weeks of daily dosing: placebo, 80mg/m2/day, 160mg/m2/day.

Key study objectives will include:

  • To confirm the safety and tolerability of oral vorinostat 80mg/m2/day and 160mg/ m2/day dose levels when administered to typical Rett patients
  • To identify the nature and magnitude of treatment response to vorinostat, as measured by changes in clinical and laboratory parameters indicative of trend towards benefit, as well as changes in mRNA expression (transcriptome response)
  • Provide a data-driven justification for future study design and statistical analysis plan for subsequent clinical studies assessing safety and efficacy of vorinostat in Rett syndrome
Read the detailed description

Unravel Biosciences, Inc. ("Unravel") proposes to develop an orally administered, once daily novel treatment for the orphan drug indication of Rett syndrome. Unravel has utilized its proprietary drug discovery platform to identify drugs having potential therapeutic value for neurodevelopmental disorders caused by gene mutations shown to have a cascading effect on other genes. Unravel's platform combines human gene regulatory network-based computational drug prediction with in vivo screening in a population-level diversity, CRISPR-edited, Xenopus laevis tadpole model of Rett syndrome.

Through use of Unravel's platform, the drug vorinostat ranked highly in predictive scoring, including when compared to trofinetide, which served as an active control in the screening evaluation (Novak, et.al., 2022). Vorinostat broadly improved both CNS and non-CNS (e.g., gastrointestinal, respiratory, inflammatory) abnormalities in a pre-clinical mouse model of Rett syndrome. Vorinostat was the first Rett syndrome treatment to demonstrate nonclinical efficacy across multiple organ systems when dosed after the onset of symptoms, and network analysis revealed a putative therapeutic mechanism for its cross-organ normalizing effects based on its impact on acetylation metabolism and post-translational modifications of microtubules, leading to the selection of vorinostat as a target candidate for further assessment in Rett syndrome.

The main hypotheses informing the goals and design of the study are as follows:

  • Vorinostat is safe and tolerable when dosed in typical Rett patients at dose levels up to 160mg/m2/day
  • At a molecular level, vorinostat mitigates the impact of the underlying MECP2 gene deficiency in Rett patients by restoring downstream mRNA synthesis, as measured by transcriptome data
  • Vorinostat provides clinical benefit to Rett patients by reducing frequency and severity of clinical signs/symptoms and improving patient quality of life

The study is designed as an exploratory, proof of concept trial to investigate the study hypotheses as stated above and to achieve the primary goals of the trial. The study design adapts the well-known "n of 1" crossover study methodology (Guyatt, et.al., 1990, Kravitz, et.al., 2014), where each patient serves as their own control during comparative analyses of safety and efficacy. Up to 15 patients will be enrolled in the study to explore the hypothesis that vorinostat is a safe and potentially effective treatment for typical Rett syndrome.

Each patient enrolled in the study will be exposed to a 4-week placebo study phase to generate baseline data that will serve as a control as well as two active drug phases with vorinostat treatment, starting at 80mg/m2/day dosing for 8 weeks, followed by dose escalation to 160mg/m2/day for 8 weeks.

The study is designed to be single-blinded, where patients and their caregivers will not be aware of their treatment assignment in an attempt to minimize bias where practically possible, especially given the subjective nature of several of the endpoints being evaluated. Investigator, study staff, and sponsor will not be blinded to study treatment assignment.

02

Conditions studied

  • Rett Syndrome

Browse trials for

Keywords

  • n of 1
  • single blinded
  • interventional
  • rett syndrome
03

In context

Rett Syndrome

96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.

This study's planned enrollment of 15 is below the median of 30 across 64 interventional studies indexed under Rett Syndrome.

Browse Rett Syndrome studies →

Lead sponsor

Unravel Biosciences, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 21 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female subjects ≥6 years of age and ≤ 21 years of age at time of screening
  2. Has typical Rett Syndrome (RTT), based on diagnostic criteria for RTT described in Neul, et.al., 2010
  3. Has documented, disease causing mutation in the MeCP2 gene
  4. At time of screening, is in the post-regression phase with no degradation of ambulation, hand function, speech or communication skills in the 4 months prior to screening
  5. Has been on a stable regimen of medication or non-pharmacological treatment for at least 4 weeks prior to the baseline visit; if currently taking trofinetide (Daybue), currently on stable dose for the previous 6 months before screening visit
  6. Has had a stable pattern of seizure activity for 4 weeks before screening
  7. Can swallow medication or can take it by gastrostomy tube
  8. Can wear actigraphy data logging device on wrist or ankle
  9. If of , must agree to use a highly effective method of during the study and for 3 months after the last study drug administration (i.e., abstinence from sexual activity, hormonal contraceptives associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system)
  10. Subjects or their legally authorized representative must be able to provide an and have sufficient language skill to complete caregiver assessments in the language in which the study assessments are provided

Exclusion criteria

Exclusion Criteria:

  1. Has another medical condition other than those related to MeCP2 mutation (e.g. diabetes mellitus, cardiovascular disease, renal disease, respiratory disease, hematological abnormalities, )
  2. Has major surgery planned during the study period
  3. Pregnant or nursing women
  4. Has a history of brain injury, stroke, other cerebrovascular disease or hypoxic-ischemic encephalopathy
  5. Has clinically significant abnormal vital signs at screening or baseline
  6. Has an abnormal at screening, including clinically significant
  7. Has a clinically significant abnormal laboratory value at screening
  8. Liver disease or transaminase levels > 1.5 times the as determined during screening
  9. Has a history of malignancy of any organ system within the past 5 years before screening
  10. Is participating in or has participated in another clinical trial within 30 days prior to the screening visit
  11. Has been treated with growth hormone, IGF-1, or insulin within 12 weeks of baseline
  12. Is taking anticoagulant therapy or other HDAC inhibitors
  13. Has had any change to their medication or non-pharmacological treatment within 4 weeks prior to the baseline visit
  14. of less than 12 months.
  15. Has a history of alcoholism or drug/chemical abuse within 2 years before screening.
  16. In the investigator's opinion, is inappropriate for this study for any reason
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Low dose interventional arm

    80mg/m2/day dose vorinostat

    Drug: Vorinostat (SAHA)

  • Experimental
    High dose interventional arm

    160mg/m2/day dose vorinostat

    Drug: Vorinostat (SAHA)

  • Placebo comparator
    Placebo

    placebo

    Drug: Placebo

Interventions

  • oral suspension

    Also known as: suberoylanilide hydroxamic acid

  • DrugPlacebo

    placebo

06

What researchers measure

Primary outcomes

  1. Frequency of treatment-related adverse events

    Treatment-related adverse events coded by MedDRA will be compared qualitatively between low dose treatment, high dose treatment, and placebo groups.

    Time frame: 20 weeks

  2. Tolerability as measured by number of treatment discontinuations

    The number of patients discontinuing treatment due to adverse events will be assessed between low dose treatment, high dose treatment, and placebo groups

    Time frame: 20 weeks

  3. Change in transcriptomic profile from baseline, as measured by RNA-seq (transcriptome biomarker analysis)

    Transcriptome biomarker analysis is widely used to assess dynamic changes in biological systems in response to disease processes and applied stimuli, which cannot be captured with genomic sequencing of DNA mutations and variations. Unravel Biosciences has created a proprietary algorithm for analyzing transcriptome data, identifying underlying signatures of disease progression or recovery. The machine learned gene network approach predicted the use of vorinostat based on restoring a transcriptome signature of Rett syndrome toward a healthy state, which was confirmed preclinically and motivated this clinical trial. The same algorithm will be used to assess time-dependent changes in the transcriptome network signature, to evaluate its ability to capture clinical response data and to measure the extent of restoration of a disease signature back to a healthy state in a human relative to pre-clinical models.

    Time frame: 20 weeks

Secondary outcomes

  1. Change from baseline on the Rett-anchored Clinical Global Impression Improvement Scale (CGI-I)

    7 point Likert scale with 1=very much improved and 7=very much worse

    Time frame: 20 weeks

  2. Change from baseline in Rett-anchored Clinical Global Impression Severity Scale (CGI-S)

    7 point Likert Scale; 1=normal, 7=extremely ill

    Time frame: 20 weeks

  3. Change from baseline in Rett Syndrome Behavior Questionnaire (RSBQ)

    The 45-item RSBQ is rated on a Likert 2-point scale and consists of eight subscales: general mood, breathing abnormalities, hand behaviors, repetitive face movements, body rocking and expressionless face, night-time behavior, fear/anxiety, and walking/standing, with ratings reflecting severity and frequency of symptoms. A total score, representing the sum of the 45 items (maximum score 90), and 8 subscale scores are obtained. A lower score represents lower symptom intensity.

    Time frame: 20 weeks

  4. Change from baseline in the Revised Motor Behavioral Assessment (R-MBA)

    Each of the 24 assessment items are scored based on observed or recently reported severity/frequency and scored on a five-point Likert scale between 0 and 4, with higher numbers denoting higher levels of severity/frequency.

    Time frame: 20 weeks

  5. Change from baseline in the Caregiver Impression of Improvement (CareGI-I)

    A 5-point Likert scale is used with the following response options: Much Improved (1); Improved (2); Unchanged (3); Worse (4); or Much Worse (5).

    Time frame: 20 weeks

  6. Reduction in frequency of seizures as measured by seizure diary

    Caregiver-recorded seizure frequency, duration, and quality will be evaluated for evidence of improvement based on reduction in seizure burden

    Time frame: 20 weeks

  7. Changes in sleeping habits as measured by modified Child Sleep Habits Questionnaire (CSHQ)

    A modified version of the 45-item caregiver questionnaire will be used. Items are rated on a three-point scale: "usually" if the sleep behavior occurred five to seven times/week; "sometimes" for two to four times/week; and "rarely" for zero to one time/week. Lower scores are suggestive of lower disease burden on sleep behavior

    Time frame: 20 weeks

  8. GI symptom measures relative to baseline using a subset of questions from the Gastrointestinal Symptom Rating Scale (GSRS)

    A subset of 7 questions from the GSRS will be used in the study, each question rated on a 4 point ordinal scale, "0" representing no symptoms and "3" representing significant symptom burden. Lower scores reflect lower symptom burden.

    Time frame: 20 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Sep 2, 2025
StartActual
Mar 15, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 15, 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07150013
Lead sponsor
Unravel Biosciences, Inc.
Responsible party
Sponsor
First posted
Sep 2, 2025
Start date
Mar 15, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Neal I Muni, M.D., MSPH
Contact
neal.muni@unravel.bio
+1 857-404-8252
Neal I Muni, M.D., MSPH
study director · Unravel Biosciences, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion